DMD Noab BioDiscoveries - Shaping Drug Discovery

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Drug Metabolism and Disposition Fast Forward
First published on July 12, 2007; DOI: 10.1124/dmd.107.016170

0090-9556/07/3510-1963-1969$20.00
DMD 35:1963-1969, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.107.016170v1
35/10/1963    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barnes, S. N.
Right arrow Articles by Manautou, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barnes, S. N.
Right arrow Articles by Manautou, J. E.

Induction of Hepatobiliary Efflux Transporters in Acetaminophen-Induced Acute Liver Failure Cases

Sarah N. Barnes, Lauren M. Aleksunes, Lisa Augustine, George L. Scheffer, Michael J. Goedken, Amy B. Jakowski, Ingrid M. Pruimboom-Brees, Nathan J. Cherrington, and José E. Manautou

Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut (S.N.B., L.M.A., J.E.M.); Department of Pharmacology and Toxicology, University of Arizona, Tucson, Arizona (L.A., N.J.C.); Department of Pathology, VU Medical Center, Amsterdam, The Netherlands (G.L.S.); and Department of Pathology and Drug Safety Research and Development, Pfizer Global Research and Development, Groton, Connecticut (M.J.G., A.B.J., I.M.P.-B.)

Alterations in transporter expression may represent a compensatory mechanism of damaged hepatocytes to reduce accumulation of potentially toxic compounds. The present study was conducted to investigate the expression of hepatobiliary efflux transporters in livers from patients after toxic acetaminophen (APAP) ingestion, with livers from patients with primary biliary cirrhosis (PBC) serving as positive controls. mRNA and protein expression of multidrug resistance-associated protein (MRP) 1-6, multidrug resistance protein (MDR) 1-3/P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP) in normal (n = 6), APAP overdose (n = 5), and PBC (n = 6) human liver samples were determined by branched DNA and Western blot analysis, respectively. Double immunohistochemical staining of P-gp and proliferating cell nuclear antigen (PCNA), a marker of proliferation, was performed on paraffin-embedded tissue sections. Compared with normal liver specimens, MRP1 and MRP4 mRNA levels were elevated after APAP overdose and in PBC. Up-regulation of MRP5, MDR1, and BCRP mRNA occurred in PBC livers. Protein levels of MRP4, MRP5, BCRP, and P-gp were increased in both disease states, with MRP1 and MRP3 protein also being induced in PBC. Increased P-gp protein was confirmed immunohistochemically and was found to localize to areas of PCNA-positive hepatocytes, which were detected in APAP overdose and PBC livers. The findings from this study demonstrate that hepatic efflux transporter expression is up-regulated in cases of APAP-induced liver failure and PBC. This adaptation may aid in reducing retention of byproducts of cellular injury and bile constituents within hepatocytes. The close proximity of P-gp and PCNA-positive hepatocytes during liver injury suggests that along with cell regeneration, increased efflux transporter expression is a critical response to hepatic damage to protect the liver from additional insult.

Address correspondence to: Dr. José E. Manautou, Toxicology Program, Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, 69 North Eagleville Rd., Unit 3092, Storrs, CT 06269-3092. E-mail: jose.manautou{at}uconn.edu




This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
S. R. Miranda, J. K. Lee, K. L. R. Brouwer, Z. Wen, P. C. Smith, and R. L. Hawke
Hepatic Metabolism and Biliary Excretion of Silymarin Flavonolignans in Isolated Perfused Rat Livers: Role of Multidrug Resistance-Associated Protein 2 (Abcc2)
Drug Metab. Dispos., November 1, 2008; 36(11): 2219 - 2226.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. J. Schrieber, Z. Wen, M. Vourvahis, P. C. Smith, M. W. Fried, A. D. M. Kashuba, and R. L. Hawke
The Pharmacokinetics of Silymarin Is Altered in Patients with Hepatitis C Virus and Nonalcoholic Fatty Liver Disease and Correlates with Plasma Caspase-3/7 Activity
Drug Metab. Dispos., September 1, 2008; 36(9): 1909 - 1916.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
L. M. Aleksunes, S. N. Campion, M. J. Goedken, and J. E. Manautou
Acquired Resistance to Acetaminophen Hepatotoxicity is Associated with Induction of Multidrug Resistance-Associated Protein 4 (Mrp4) in Proliferating Hepatocytes
Toxicol. Sci., August 1, 2008; 104(2): 261 - 273.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
S. N. Campion, R. Johnson, L. M. Aleksunes, M. J. Goedken, N. van Rooijen, G. L. Scheffer, N. J. Cherrington, and J. E. Manautou
Hepatic Mrp4 induction following acetaminophen exposure is dependent on Kupffer cell function
Am J Physiol Gastrointest Liver Physiol, August 1, 2008; 295(2): G294 - G304.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.